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Abstract
Background: Previous studies have demonstrated that the presence of serum IgA antibodies against actin
filaments (AAA) in patients with celiac disease (CD) is strongly associated with mucosal damage and severe
degrees of villous atrophy.
The aims of the present study were (1) to verify the effectiveness of IgA-AAA in newly diagnosed CD patients in a
clinical setting (2) to compare the immunofluorescence assay with ELISA assay; (3) to compare the correlation of
our IgA anti-tissue transglutaminase antibodies (tTG-Ab) class with mucosal intestinal lesions.
Methods: 90 patients underwent endoscopy and multiple biopsies for suspected CD on the basis of symptoms, in
presence of positive tTG-Ab tests. Twenty biopsied and 25 not-biopsied subjects with negative tTG-Ab were tested
as control groups.
IgA-AAA assays were performed by indirect immunofluorescence using rat epithelial intestinal cells, and by ELISA
with a commercial kit. tTG-Ab assay was a radio-binding assay.
Intestinal specimens were collected by upper endoscopy and the histological study was done according to the
Marsh’s classification modified by Oberhuber (M/O). Auto-antibodies assays and histological evaluation have been
performed blindly by skilled operators.
Results: CD diagnosis was confirmed in 82 patients (type I M/O in 2 patients, IIIA in 18 patients, IIIB in 29 patients
and IIIC in 33 patients). Two patients with type 1 lesion in presence of positive tTG-Ab and abdominal complaints,
started a gluten free diet.
The rate of IgA-AAA positivity (sensitivity) by IFI and ELISA in histologically proven celiac disease patients, were
5.5% and 25% patients in IIIA, 27.5% and 34.4% patients in IIIB, 78.8% and 75% in IIIC patients, respectively.
Patients with normal or nearly normal mucosa, regardless of tTG-Ab status, presented negative IgA-AAA IFI assay.
On the other hand, 1 patient with normal mucosa but positive tTG-Ab, also presented positive IgA-AAA ELISA. All
healthy non biopsied controls had negative IgA-AAA. tTG-Ab serum concentration was significantly correlated with
more severe intestinal lesion (IIIB, IIIC M/O).
Conclusions: IgA-AAA may be undetectable in presence of severe mucosal damage. Histology is still necessary to
diagnose celiac disease and IgA-AAA cannot be included in usual screening tests, because it has little to offer if
compared to the well-established tTG-Ab.
IgA-AAA could be an adjunctive, very useful tool to support the diagnosis of CD in case of suboptimal histology,
when the biopsy is to be avoided for clinical reasons, or in case of negative parents’ consensus.
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Background
Celiac disease (CD) is a permanent, immune-mediated
enteropathy caused by gluten ingestion in genetically
susceptible subjects. It is characterized by various
degrees of villous atrophy in presence of gluten-depen-
dent autoantibodies [1,2].
The prevalence of CD is currently increasing com-
pared to our experience in the past. Serological findings,
such as anti-endomysium (EmA) and anti-tissue-trans-
glutaminase antibodies (tTG-Ab), are very useful in
increasing our diagnostic capacity [3-5], but are not
always able to predict the histological features [6-8].
The pathogenic cascade that causes the typical histolo-
gical lesions, characterized by flat mucosa with tissue
destruction and reorganization of the intestinal picture,
is still partially unknown. In this respect, a role of cytos-
keleton has been described: the gluten ingestion has
been reported to induce a rapid alteration of the actin
network on intestinal mucosa of CD patients [9]. Glia-
din rapidly increases actin polymerization leading to
rearrangement of actin filaments, especially in the intra-
cellular subcortical compartment [10]. It is likely that
newly generated actin polymers may be exposed to gut-
associated lymphatic tissue, causing the production of
IgA antibodies against actin filaments (IgA-AAA).
Previous studies have described that the presence of
antibodies against actin filaments is associated with
severe degrees of mucosal damage and that IgA-AAA
may also contribute to exacerbate the villous’ cytoskele-
ton damage [11-14]. It has also been suggested that the
presence of IgA-AAA may, in some patients, overcome
the need of the intestinal biopsy [9].
The aims of this study were to evaluate, using two dif-
ferent assays (immunofluorescence (IFI) and ELISA), the
prevalence of IgA-AAA in a group of newly diagnosed
CD patients and to verify the relationship between these
serological tests and degrees of intestinal lesions. Finally,
we verified the reliability of our tTG-Ab IgA test in pre-
dicting intestinal mucosal damage.
Methods
Patients
We enrolled between November 2006 and March 2008:
- 90 patients (59 F, 31 M, age mean ± SD: 6.8 ± 4.1
yrs), who performed endoscopy and multiple biop-
sies for suspected CD, on the basis of symptoms and
positive tTG-Ab. Twenty patients had a typical pre-
sentation, characterized by gastrointestinal com-
plaints (malabsorption syndrome, abdominal pain,
prominent abdomen), 34 patients had non-intestinal
presentation (anemia, failure to thrive, dermatitis),
and 36 patients were identified during screening
program in at risk groups (type I diabetes, autoim-
mune disease, first degree relatives of CD);
- 45 control subjects, matched for age and sex, with
negative tTG-Ab tests: 20 underwent endoscopy for
persistent GI symptoms (dyspepsia in 12; recurrent
abdominal pain in 8 patients).
Informed consent to the study was obtained from all
patients and control subjects’ parents or legal guardians.
The study was performed in accordance to the princi-
ples of the Declaration of Helsinki.
Autoantibodies measurements
- IgA and IgG antibodies to recombinant human tis-
sue transglutaminase C were measured by radio-
binding assay as previously described [15]. Results
for each assay were expressed as arbitrary units
derived from standard curves of serial dilutions of a
serum with both IgA and IgG tTG tested in each
assay [ranges tTG IgA 0-1.3 AU; tTG IgG 0-8 AU].
- IgA-AAA were evaluated by indirect immunofluor-
escence on sections containing rat epithelial intest-
inal cells (Eurospital, Trieste-Italy). A 1:5 dilution of
serum sample from each patient and positive control
were incubated at 56°C for 30 min. The slides were
examined under a fluorescence microscope (Leitz
Laborlux) using 250-400× magnifications (Figure 1).
Fluorescence was compared with positive and nega-
tive control samples tested in each assay.
- The detection of IgA AAA by ELISA was con-
duced using a commercially available assay (Quanta
Lite™ F-actin IgA INOVA, 704500) [13]. The thresh-
old was: positive more than 25 U, border-line 20.1-
24.9, negative ≤ 20.
Autoantibodies assays have been performed blindly by
a single skilled operator (E.B.).
Intestinal histology
We acquired biopsy specimens in the 4 quadrant of the
second part of the duodenum, on the first fold distal to
the papilla of Vater, according to the guidelines for the
diagnosis of CD [16]. The histological specimens were
fixed in 10% formalin and stained with hematoxylin and
eosin. The biopsy’s grading was made according to the
Marsh’s classification modified by Oberhuber et al (M/
O) [17].
Histological evaluations have been performed blindly
by a single skilled operator (L.A.).
Diagnosis of CD
Diagnosis of CD was made according to the following
criteria:
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- histological lesions type II or III according to M/O,
in presence of tTG-Ab regardless of intestinal
symptoms;
- minimal mucosal lesions (type I M/O) in presence
of tTG-Ab positivity and gluten sensitivity with clini-
cal manifestations.
Statistical analysis
The distribution of categorical variables has been evalu-
ated by chi-square test.
The differences between patients with negative or
positive IgA-AAA IFI/ELISA have been determined by
unpaired t-test.
The differences of tTG-Ab values between patients
grouped according to biopsies grading have been evalu-
ated by one-way analysis of variance (ANOVA).
Data are shown as mean ± SD, unless otherwise
stated.
Results
CD diagnosis was confirmed in 82 subjects: 18 patients
presented IIIA lesion, 29 patients presented IIIB lesion
and 33 patients had IIIC lesion; two patients had type 1
lesion in presence of positive tTG-Ab and abdominal
complaints. The gastrointestinal manifestations of the lat-
ter patient can be referred to as minimal immunopatho-
logical changes in the intestine exposed to gluten even in
the absence of overt CD enteropathy: this condition is
called “gluten sensitivity” and is defined by some mor-
phological, immunological, or functional disorder that
generally respond to gluten exclusion [18]. All patients
started a gluten free diet following the diagnosis.
Eight patients with positive tTG-Ab presented normal
mucosa (type 0 M/O). All 20 biopsied controls with
negative tTG-Ab had normal histology. The tTG-Ab
serum concentration of patients with IIIC M/O (66.14 ±
33.8 AU) or IIIB M/O (53.16 ± 30.76 AU) were higher
than IIIA intestinal lesion (32.36 ± 29.98 AU, F = 3.4;
p = 0.0123). The 8 patients with normal mucosa and
the two ones with minor lesions (type I M/O) presented
a low tTG-Ab titre (15.85 ± 11.50 AU).
IgA-AAA tested by IFI and ELISA were detected in 35
(43.7%) and in 38 (47.5%) untreated celiac patients,
respectively.
The rate of IgA-AAA positivity by IFI and ELISA in
histologically proven celiac disease patients, were 5.5%
and 25% patients in IIIA, 27.5% and 34.4% patients in
IIIB, 78.8% and 75% in IIIC patients, respectively: show-
ing an high sensitivity in predicting severe intestinal
damage.
IgA-AAA were not detectable in control subjects; just
one biopsied subject resulted positive to IgA-AAA
tested by ELISA.
Positivity rate to IgA-AAA was different according to
histological degree of lesion, as explained in table 1.
Sensitivity, sensibility, negative and positive predictive
values of IgA-AAA tested by IFI and ELISA are shown
in table 2. We found that subjects with negative IgA-
AAA IFI test had significantly lower IgA-AAA concen-
tration measured by ELISA, compared to subjects with
positive results by IFI (Wilcoxon Z: 4.89, p < 0.0001).
tTG-Ab assay was plotted against mucosal lesion
degree and results are shown in figure 2 (Significant dif-
ferences between groups were shown by analysis of var-
iance F = 6.7; p = 0.0021).
Discussion
The diagnosis of celiac disease relies on the demonstra-
tion of intestinal histological lesions associated with pre-
sence of positive gluten-autoantibodies and or clinical
improvement after gluten free diet.
Figure 1 Fluorescence images at microscopy (400×). The positive assay is represented by fluorescent cytoplasmatic parallel actin filaments on
rat epithelial intestinal cells.
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Endoscopic biopsy is an useful tool, but it is often per-
ceived as invasive and dangerous. IgA-AAA has been pro-
posed as a serological marker of intestinal mucosa damage
as it seems to correlate with histological lesions.
Recent studies suggest that IgA-AAA test could be con-
sidered a useful tool in diagnosis of CD, being a reliable
marker of severe intestinal mucosal damage. In this
respect the immunofluorescence assay has been suggested
as an useful method and ELISA has been demonstrated to
be an accurate assay for their determination [11-13].
To add our experience to these data, we studied IgA-
AAA antibodies by two different assays (IFI and ELISA),
that resulted positive in a similar proportion in newly
diagnosed CD patients (43.7% and 47.5%, respectively).
Our data confirm that serum IgA-AAA were more
frequently positive in presence of total villous atrophy
than in patients with subtotal or mild villous atrophy.
Patients with normal mucosa, regardless of tTG-Ab
status, presented negative IgA-AAA by IFI assay, thus
showing a specificity of 100%.
Because previous reports [19-22] indicated a possible
association between IgA-AAA positivity and inflamma-
tory bowel disease or autoimmune/infective hepatic dis-
orders, all patients were investigated for inflammatory
indices and hepatic function. None of the tested subject
had altered biochemical indices.
These results are apparently in contrast with data pre-
viously described in literature [11] that showed higher
sensitivity of IgA-AAA due to the presence of IgA-AAA
reactivity also in subtotal mild mucosal involvement.
This discordance could be explained by some technical
bias related to measurements methods, as recently
reported [23]. It has been underlined that the sensitivity
of IgA-AAA assay can significantly be enhanced by
heating or chelating with calcium the serum samples
before performing IgA-AAA test. We did not perform
such treatment because we strictly followed the manu-
facturer’s instructions.
Although IFI assays are operator-dependent techni-
ques, we believe that this case does not apply to our
study because the operator that performed IFI test is a
skilled one and the results obtained by IFI are not differ-
ent from data obtained by ELISA.
On the other hand, tTG-Ab were able to distinguish
patients with severe lesions (M/O type 3) from those with
milder ones (M/O type 0-1); as recently described [23,24],
we can confirm that IgA-AAA assay does not add to tTG-
Ab assay better performances in sensibility, specificity and
correlation with the degree of intestinal lesion.
Conclusions
In conclusion, histology remains the corner stone for
diagnosis of CD and our data demonstrate that the IgA-
Table 1 IgA-AAA positivity by IFI and ELISA in biopsied controls and CD subjects.
Marsh Oberhuber classification
















0 0 0 1 (5.5%) 8 (27.5%) 26 (78.8%)
Positive
IgA-AAA ELISA (%)
1 (3.3%) 0 0 4 (25%) 11 (39.3%) 24 (75%)
Table 2 Sensitivity, specificity, negative predictive value, positive predictive value of IFI and ELISA methods
of IgA-AAA
Sensitivity Specificity Negative predictive value Positive predictive value
IgA-AAA IFI 42,68% 100% 37% 100%
IgA-AAA ELISA 47,56% 96,43% 38,57% 97,50%
Figure 2 tTG-Ab titres in different mucosal lesions’ degrees
(p = 0.0021).
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AAA assay is not useful in the standard work-up for the
diagnosis of CD, particularly because it is not able to
identify mild and subtotal villous atrophy. Nevertheless,
the IgA-AAA presence suggests that the ingestion of
gluten had already caused advanced intestinal mucosal
lesions and that IgA-AAA measurement could have a
role to support the diagnosis of CD when the histology
interpretation is difficult (i.e. patchy distribution), when
the biopsy is avoided for clinical reasons (i.e. when a
biopsy or anesthesia represents a life-threatening risk),
or in case of negative parents’ consensus to endoscopy.
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